Seagen→Pfizer
Acquisition · Cash + Stock · announced Mar 13, 2023
Announced
Mar 13, 2023
Closed
Dec 14, 2023
Economics
Cash + Stock()
Pre-deal · pre-deal mark: 2023, year precision · rounding grid ±$100M · Pfizer 8-K filing, SEC EDGAR — Seagen acquisition (NASDAQ:SGEN market cap)
$229/share, ~$43B enterprise value
Target
Seagen
Precision Medicine · Clinical / therapeutic
HQ Bothell, WA · Founded 1998
Antibody-drug conjugate (ADC) oncology platform — Adcetris, Padcev, Tukysa (HER2+ breast cancer), and Tivdak (cervical cancer)
- SEC EDGAR — Pfizer 8-K (Mar 13, 2023)
- Business Wire — Pfizer/Seagen merger announcement (Mar 13, 2023)
- SEC EDGAR — Pfizer 8-K completion (Dec 14, 2023)
Acquirer
Pfizer
Healthcare
HQ New York, NY
Global pharmaceutical and biotechnology company — oncology portfolio includes breast cancer therapies via Seagen ADC platform
Why this buyer
Curated copy from the verified dataset — not an 8-K LLM summary
Largest oncology M&A in history — Seagen's ADC platform (Adcetris, Padcev, Tukysa, Tivdak) transforms Pfizer into top-tier oncology company; Tukysa targets HER2+ breast cancer, Tivdak targets cervical cancer
Evidence ladder
Primary (regulatory / filing)
SEC EDGAR — Pfizer 8-K (Mar 13, 2023)
Secondary (press / IR)
Business Wire completion announcement (Dec 14, 2023)
Primary (regulatory / filing)
SEC EDGAR 8-K https://www.sec.gov/Archives/edgar/data/78003/000119312523068538/d408093d8k.htm
Open source
Limitations
- $229/share, ~$43B enterprise value
- Pre-deal valuation sourced from: Pfizer 8-K filing, SEC EDGAR — Seagen acquisition (NASDAQ:SGEN market cap). Pre-deal market-cap and funding citations do not corroborate the acquisition.
Valuation peers · Precision Medicine
Same sector, same deal type, announced within ±3 years, disclosed value within 0.25×–4× of this transaction. Ranked by evidence class, then same acquirer.
| Target | Acquirer | Announced | Value | Why included |
|---|---|---|---|---|
| Varian Medical Systems | Siemens Healthineers | Aug 2, 2020 | same evidence class |
Same-sector adjacency — not valuation peers
These deals share the sector tag and window but sit outside the 0.25×–4× value band. The dataset keeps them for clinical adjacency, not as price comps.
| Target | Acquirer | Announced | Value | Vs this deal |
|---|---|---|---|---|
| GRAIL | Illumina | Sep 21, 2020 |
Patient empowerment context
Empowerment context — Seagen
Curated survey mappingHLTH/Outcomes4Me 2022 surveyed breast cancer patients (n=1,828). Breast cancer care continuum (HLTH 2022). Rows below are analyst-curated mappings to cited survey items — not live patient outcomes for this target.
- Presented with clinical trial as treatment option (Press release)1 in 5cited HLTH 2022Mapping source →
- No survivorship care plan after active treatment (Press release)54%cited HLTH 2022Mapping source →
- Oncologist listens; wishes reflected in treatment plan (Press release)56%cited HLTH 2022Mapping source →
- Not aware of survivorship resources (Press release)2 in 3cited HLTH 2022Mapping source →
Other curated mappings on these gaps: Biotheranostics, Genomic Health, Foundation Medicine, Flatiron Health
Full cited gap matrix →Related verified workspaces
Lacuna is a curated public-source sample, not a census of women's-health M&A. Coverage varies by sector, geography, disclosure availability, and women's-health scope. Undisclosed transaction values are excluded from disclosed-value totals.
Curated verified dataset v9 · updated 2026-09-20 · 3 citations on this deal · Data compiled from public sources for educational visualization. Verify independently before any commercial use.